EPIZYME INC's ticker is EPZM and the CUSIP is 29428V104. A total of 128 filers reported holding EPIZYME INC in Q2 2021. The put-call ratio across all filers is 1.31 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2021 | $50,000 | -59.3% | 20,000 | -16.8% | 0.00% | -66.7% |
Q3 2021 | $123,000 | -43.3% | 24,037 | -8.1% | 0.00% | -40.0% |
Q2 2021 | $217,000 | -1.4% | 26,161 | +3.7% | 0.01% | 0.0% |
Q1 2021 | $220,000 | -20.6% | 25,227 | -1.2% | 0.01% | 0.0% |
Q4 2020 | $277,000 | -15.0% | 25,534 | -6.5% | 0.01% | -44.4% |
Q3 2020 | $326,000 | -10.7% | 27,304 | +20.1% | 0.01% | -10.0% |
Q2 2020 | $365,000 | -6.2% | 22,725 | -9.4% | 0.01% | -33.3% |
Q1 2020 | $389,000 | -47.3% | 25,077 | -16.4% | 0.02% | +25.0% |
Q4 2019 | $738,000 | +10.1% | 30,000 | -53.8% | 0.01% | -14.3% |
Q3 2019 | $670,000 | -17.9% | 65,000 | 0.0% | 0.01% | -36.4% |
Q2 2019 | $816,000 | -12.2% | 65,000 | -13.3% | 0.02% | -4.3% |
Q1 2019 | $929,000 | +77.3% | 75,000 | -11.8% | 0.02% | +4.5% |
Q4 2018 | $524,000 | +23.6% | 85,000 | +112.5% | 0.02% | +100.0% |
Q3 2018 | $424,000 | +14.6% | 40,000 | +46.3% | 0.01% | +22.2% |
Q2 2018 | $370,000 | +39.1% | 27,341 | +82.3% | 0.01% | +12.5% |
Q1 2018 | $266,000 | – | 15,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RP Management, LLC | 31,833,334 | $47,750,000 | 19.42% |
MPM BioImpact LLC | 3,425,202 | $3,939,000 | 1.06% |
Palo Alto Investors LP | 6,774,541 | $7,791,000 | 0.60% |
Foresite Capital Management I, LLC | 143,759 | $165,000 | 0.29% |
PLATINUM INVESTMENT MANAGEMENT LTD | 6,603,870 | $7,594,000 | 0.23% |
Rock Springs Capital Management LP | 7,267,696 | $8,358,000 | 0.21% |
BP PLC | 24,687 | $28,000 | 0.16% |
NewGen Asset Management Ltd | 250,000 | $288,000 | 0.13% |
GSA CAPITAL PARTNERS LLP | 467,836 | $538,000 | 0.07% |
Frazier Life Sciences Management, L.P. | 739,369 | $850,000 | 0.07% |